Galectin Therapeutics Inc Stock Price, News & Analysis

Galectin Therapeutics (NASDAQ: GALT) announced positive outcomes from its third Data and Safety Monitoring Board (DSMB) meeting for the NAVIGATE study, which evaluates belapectin for preventing esophageal varices in patients with liver cirrhosis due to non-alcoholic steatohepatitis (NASH). The global study includes 357 randomized patients across 14 countries. The DSMB confirmed that the trial can continue without changes, reinforcing confidence in belapectin's safety profile. Interim data from Phase 2b is anticipated in Q4 2024, highlighting the critical need for effective treatments as NASH prevalence rises, contributing to increased liver cirrhosis cases worldwide.

Galectin Therapeutics (NASDAQ: GALT) has completed patient enrollment for its NAVIGATE study, focusing on belapectin for liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). The study exceeded its target, randomizing 357 patients across 14 countries, aiming to prevent esophageal varices in patients with portal hypertension. The treatment period for the phase 2b portion spans 18 months, with topline results anticipated in Q4 2024. The Chief Medical Officer expressed optimism regarding the potential benefits of belapectin, while the CEO highlighted the company's focus on efficient execution of its program following this milestone.

Galectin Therapeutics (NASDAQ:GALT) announced the publication of a scientific paper examining the use of a machine learning histology model for liver biopsies in nonalcoholic steatohepatitis (NASH) cirrhosis. The study, conducted in collaboration with top U.S. academic centers, highlights the limitations of traditional histology techniques and demonstrates how advanced technology can assess key fibrotic features.

Dr. Pol Boudes emphasized that innovative methods could enhance drug development processes. Belapectin, the company’s lead drug, aims to disrupt galectin-3 functionality, crucial in liver scarring. This research supports Galectin's ongoing NAVIGATE trial aimed at addressing liver fibrosis.

Galectin Therapeutics (NASDAQ: GALT) has completed enrollment for the NAVIGATE study, a Phase 2b/3 trial focused on belapectin for preventing esophageal varices in NASH cirrhosis. Conducted across 14 countries, the study randomized 309 patients, with final numbers projected between 325-340. Interim results are expected by Q4 2024. Belapectin targets galectin-3, crucial in NASH and fibrosis. This milestone enables the company to advance its program and explore other therapeutic opportunities for chronic liver disease and cancer.

Galectin Therapeutics (NASDAQ:GALT) announced a corporate update will be presented via live webcast after its 2022 Annual Meeting of Stockholders on December 1, 2022, starting at 11:00 a.m. ET. Shareholders can access the meeting at www.virtualshareholdermeeting.com/GALT2022. The company focuses on developing novel therapies for chronic liver disease and cancer, with its lead drug belapectin targeting NASH with advanced fibrosis, and has received Fast Track designation from the FDA.

NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ: GALT) announced its participation in the 6th Obesity and NASH Drug Development Summit, where Dr. Pol F. Boudes will discuss drug development challenges for NASH cirrhosis on November 30, 2022. The company’s lead drug, Belapectin, targets galectin-3, playing a crucial role in NASH and fibrosis treatment. With promising preclinical outcomes and a Phase 2 trial underway, Galectin aims to prevent esophageal varices in NASH cirrhosis. NASH affects up to 28 million people in the U.S., highlighting the urgent need for effective therapies.

Galectin Therapeutics, Inc. (NASDAQ: GALT) announced its financial results for Q3 2022, reporting a net loss of $8.6 million, consistent with Q3 2021. The company secured its largest financing to date, extending its cash runway through 2024, while accelerating recruitment for its pivotal NASH cirrhosis trial, NAVIGATE, with 279 out of 315 patients randomized. Additionally, Galectin received FDA approval for its IND application for belapectin in combination with Keytruda for treating head and neck cancers.

Galectin Therapeutics (NASDAQ:GALT) announced five scientific presentations at The Liver Meeting™ 2022, focusing on liver cirrhosis and portal hypertension related to non-alcoholic steatohepatitis (NASH). Key topics include the prevalence of esophageal varices, the biochemical profiles of 271 NASH cirrhosis patients, and the clinical utility of the ELF score. The company aims to showcase new data on their drug candidate Belapectin, designed to inhibit the galectin-3 protein, which is involved in liver fibrosis. These findings contribute to ongoing Phase 2b/3 studies.

Galectin Therapeutics (NASDAQ: GALT) announced its participation in two upcoming conferences. On October 17, 2022, Dr. Pol F. Boudes will present at the H.C. Wainwright 6th Annual NASH Investor Conference. The second presentation will take place on October 20, 2022, at the Discovery on Target conference, focusing on belapectin, a galectin-3 inhibitor for NASH cirrhosis. Belapectin has shown promise in preclinical studies for reversing liver fibrosis. NASH affects millions in the U.S., and belapectin is under Fast Track designation for its potential treatment.